Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. Its primary product candidate is ALXN1840 (tiomolybdate choline), a late-stage, once-daily oral medicine for Wilson disease, a rare genetic condition characterized by copper accumulation. The company also develops a series of radiopharmaceuticals targeting the urokinase plasminogen activator receptor (uPAR) in advanced cancers, including MNPR-101-Zr for imaging, MNPR-101-Lu for therapy, and MNPR-101-Ac in late preclinical stages. Monopar builds its pipeline through in-house research and the licensing of late preclinical and clinical-stage therapeutics. The company serves patients with rare diseases and advanced solid tumors, with a focus on personalized and precise cancer care. ALXN1840 has received Orphan Drug Designation in the U.S. and EU, as well as Fast Track designation from the FDA. Monopar assumed responsibility for the global development and commercialization of ALXN1840 following a license agreement with Alexion in 2024.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage monopartx.com
Sector Healthcare IR page ir.monopartx.com
Tags
wilson disease, radiopharmaceuticals, oncology, rare diseases, copper chelation, targeted therapy, clinical-stage, oral medicine, imaging agents, therapeutic agents, ALXN1840, tiomolybdate choline, MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac, uPAR, Alexion
Press page monopartx.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 483.099M
Market cap (USD) $ 483.099M
P/E -29.28
PEG —
P/BV 3.80
P/S —
P/OCF -29.70
P/FCF -39.59
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.2%
ROI -18.0%
ROIC -16.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 54
Quality score -81.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Assets 140.718M 60.291M 7.345M 13.227M 20.522M 16.869M 13.352M 7.318M 9.931M 2.896M
Net profit -13.717M -15.586M -8.402M -10.516M -9.103M -6.305M -4.225M -3.228M -16.555M -1.186M
Free cash flow -12.201M -6.404M -7.858M -7.229M -7.317M — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 65.3 22 0.34 2.37 3.22 6.16 16.62 — — —
Price performance 12m 1.97 63.71 -0.86 -0.26 -0.48 -0.63 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — — 0.00 8,408 0.00 0.00 245,489
Cash and deposits (USD) 2.07M 8.98M 6.89M 13.2M 16.7M 20.3M 8.19M 7.27M 45.8M 61.8M
Right-of-use assets (USD) — — — — — 0.00 61,228 12,646 0.00 254,921
Cash flow detail
Operating cash flow (USD) -1.19M -2.63M -2.89M -3.02M -4.66M 7.32M -7.23M -7.86M -6.4M -12.2M
Change in payables (cash effect) (USD) -9,333 247,357 87,684 243,534 447,598 — 1.48M -1.33M 506,791 388,218
Share buybacks (cash effect) (USD) — — — — — — — — 0.00 -35M
Income taxes paid (cash effect) (USD) — — — -53.00 11,099 0.00 — — — —
Share-based compensation (USD) 0.00 305,205 529,332 1.01M 1.32M 1.47M 1.64M 1.9M 1.14M 4.84M
Income detail
Research and development expense (USD) 280,355 935,319 1.77M 1.97M 4.07M 6.49M 7.59M 5.6M 13M 9.9M
↳ 5y CAGR +87.5% +52.0% +25.8% +45.9% +19.5%
Total comprehensive income (USD) — -16.6M -3.23M -4.23M -6.3M -9.1M -10.5M -8.43M -15.5M -13.6M
Comprehensive income to owners (USD) — -16.6M -3.23M -4.23M -6.3M -9.1M -10.5M -8.43M -15.5M -13.6M
Reported Mar 26, 2018 Feb 26, 2019 Feb 26, 2019 Mar 25, 2021 Mar 25, 2021 May 12, 2022 Mar 28, 2024 Mar 28, 2024 Mar 27, 2026 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Monopar Therapeutics Reports Third Quarter 2026 Bull 5 Bear 0 Results

Financial Results and Provides Business Updates

Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates.

Recent Program Developments

ALXN1840 for Wilson Disease

On November 8, 2026, Monopar presented baseline findings from the Phase 3 FoCus study of ALXN1840 (tiomolibdate choline, TMC), the largest randomized controlled trial ever conducted in Wilson disease, characterizing residual disease burden in treatment-experienced patients at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026. Baseline rates in treatment-experienced and treatment-naïve patients were 39% and 30% for cirrhosis, 79% and 83% for neurologic symptoms, and 75% and 70% for psychiatric symptoms, respectively. Among evaluable patients, 73% had at least two of these manifestations. Only 47% of treatment-experienced patients were within the guideline-recommended copper target range.

Download as PDF November 02, 2026

WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company’s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place Nov. 5–9, 2026, at the Colorado Convention Center in Denver, Colorado.

As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-naïve and treatment-experienced patients. These findings will also be available as a companion e-poster via the AASLD website.

Additionally, Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., will present a poster on molybdenum balance in patients treated with ALXN1840.

Presentation Details

Oral Presentation

Title: Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial
Presenter: Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program, University of Michigan Health System
Session: Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
Publication Number: 0198
Date and Time: Sunday, Nov. 8, 2026, 12:15 p.m. to 12:30 p.m. MT

Companion E-Poster

Availability: An e-poster of the oral presentation will be available via the AASLD website. 

Poster Presentation

Title: Neutral Molybdenum Balance and Lack of Molybdenum Toxicity in Subjects Treated with Tiomolibdate Choline Supports Safety Profile of TMC
Presenter: Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Consultant Hepatologist, Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London
Session: Poster Session I: Metabolic and Genetic Disease
Publication Number: 1420
Date and Time: Thursday, Nov. 5, 2026, 12:00 p.m. to 1:00 p.m. MT

The abstracts are available on the AASLD conference website . Presentation materials will be made available in the Investors section of Monopar’s website at www.monopartx.com following each presentation.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body’s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the regulatory and approval process for ALXN1840, and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Download as PDF August 19, 2026

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

Appointment of Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs

Upon joining Monopar, Dr. Kent will lead the Company’s medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840, its first-in-class albumin tripartite complex (ATC) activator drug candidate for the treatment of Wilson disease.

“Dr. Kent’s training as a gastroenterologist and hepatologist, combined with his deep experience in rare disease, regulatory strategy, and product launches, makes him an exceptional fit for Monopar as we prepare to bring ALXN1840 to patients with Wilson disease,” said Chandler Robinson, M.D., Chief Executive Officer of Monopar.

“The novel mechanism of action and compelling data package of ALXN1840 have the potential to meaningfully change how Wilson disease is treated,” said Dr. Kent. “I look forward to helping realize that potential for patients.”

Dr. Kent brings more than 20 years of biopharmaceutical leadership experience across medical affairs, clinical development and regulatory strategy, with expertise spanning rare diseases, hepatology and gastroenterology, immunology and specialty therapeutics. Most recently, he served as Chief Medical Officer of Sling Therapeutics, where he led the Phase 2b clinical program evaluating linsitinib in thyroid eye disease. Previously, Dr. Kent spent more than a decade at Horizon Therapeutics, including serving as Executive Vice President, Medical Affairs, and as a member of the Executive Committee. During his tenure, he built and scaled Horizon’s global medical affairs organization and supported key programs, including the KRYSTEXXA franchise and the TEPEZZA Biologics License Application (BLA) and its successful FDA Advisory Committee meeting. Earlier in his career, Dr. Kent led global medical affairs for HUMIRA at Abbott Laboratories and served on the CELEBREX clinical development team at Searle/Pharmacia.

AASLD – The Liver Meeting® 2026 Presentations

The abstract, titled “Residual hepatic, neurologic, and psychiatric disease burden in treatment-experienced patients with Wilson disease: baseline findings from the FoCus Phase 3 trial,” was selected for an oral presentation, a distinction reserved for a small share of accepted abstracts. Frederick K. Askari, M.D., Ph.D., lead author of the abstract and Associate Professor of Internal Medicine and Director of the Wilson Disease Program at the University of Michigan Health System, will present the findings on Sunday, November 8, 2026, from 12:15 p.m. to 12:30 p.m. MT. The presentation will highlight the significant unmet need that persists despite years of treatment with currently available therapies, underscoring the importance of novel treatment options in Wilson disease.

Additionally, a second abstract, titled “Neutral molybdenum balance and lack of molybdenum toxicity in subjects treated with tiomolibdate choline supports safety profile of TMC,” was selected for a poster presentation. Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Consultant Hepatologist at The Roger Williams Institute of Liver Studies, King’s College London, and King’s College Hospital, London, will present the poster during the Metabolic and Genetic Disease poster session on Thursday, November 5, 2026, from 12:00 p.m. to 1:00 p.m. MT.

The abstracts are scheduled to be released publicly by AASLD on October 5, 2026, and will be published in the October supplement of Hepatology. Presentation materials will be made available on the Monopar website concurrently with each presentation.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body’s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning the following: that Dr. Kent will lead the medical affairs organization in preparation for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that Monopar is preparing to bring ALXN1840 to patients with Wilson disease; and that the novel mechanism of action and compelling data package of ALXN1840 have the potential to meaningfully change how Wilson disease is treated. The forward-looking statements involve risks and uncertainties including, but not limited to: the risk that Dr. Kent does not commence employment as expected or that the anticipated benefits of his appointment are not realized; uncertainties related to the regulatory process, including the rolling NDA submssion, that Monopar has initiated for ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Prompts

Monopar Therapeutics Inc. (ticker MNPR), listed in United States.

ETFs Holding Monopar Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.05% 8,802 $ 985.208K Aug 31, 2026
RESM 0.01% 5 $ 462.95 Jun 30, 2026
AVSC 0.01% 3,286 $ 236.493K Nov 16, 2026